NCT00296738
Completed
Not Applicable
Quantitative 123I-MIBG SPECT/CT Assessment of Cardiac Sympathetic Innervation
ConditionsCardiac Diseases
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cardiac Diseases
- Sponsor
- Rambam Health Care Campus
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- The impact of the imaging modality on patient management
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
Myocardial scintigraphy with 123I-MIBG allows for visual and semi-quantitative assessment of sympathetic cardiac innervation using the hear to mediastinum ratio (HMR). Impaired cardiac MIBG clearance may occur in patients with congestive heart failure (CHF). The purpose of present study was to develop and validate a quantitative index for the assessment of cardiac MIBG uptake kinetics using SPECT/CT for diagnosis of CHF
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
The impact of the imaging modality on patient management
Time Frame: 2 years
Secondary Outcomes
- The impact on patient management(2 years)
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 3
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine TumorsPheochromocytomaNeuroblastomaParagangliomaMedullary Thyroid CarcinomaCarcinoid TumorsNCT01373736Vancouver Coastal Health
Unknown
Phase 2
124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.Parkinson DiseaseNeuroendocrine TumorsNCT01931488Tel-Aviv Sourasky Medical Center40
Completed
Not Applicable
Use of MIBG Scan Images in PVC AblationsPremature Ventricular ContractionsNCT02279030University of Maryland, Baltimore20
Completed
Phase 3
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or NeuroblastomaPheochromocytomaNeuroblastomaNCT00126412GE Healthcare251
Completed
Phase 1
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the BrainAlzheimer DiseaseNCT00287248Institute for Neurodegenerative Disorders38